BIBLIOGRAPHY:-

American Cancer Society. (2015) Leukemia – Acute Myeloid (Myelogenous) Cancer Facts & Figures 2015. Atlanta, Ga: American Cancer Society.

Ahmed F,Kokate P,Chheda P, Dalvi R, Ranjandas B, Mandava S.(2008),Molecular cytogenetic findings in a three –way novel variant of t(1;8;21)(p35;q22;q22):a unique relocation of the AML1/ETO fusion gene 1p35in AML-M2, Cancer Genetics and Cytogenetics,180:153-157.

Ballabio E., Biondi A., Boultwood J., Bradtke J., Bridger J. M., Garimberti E., Harbott J., Regan R., Teigler, A., Cazzaniga, G., Giudici, G., , Knight S. J. L., Tosi S., Wainscoat J. S. (2011), Genomic imbalances are confined to non-proliferating cells in pediatric patients with acute myeloid leukemia and a normal or incomplete karyotype. Plose One, 6, 6, 20607.

Baldwin, E. L., Lee, J. Y., Blake, D. M., Bunke, B. P., Alexander, C. R., Kogan, A. L., & Martin, C. L. (2008), Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. Genetics in Medicine, 10(6), 415-429.

Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., & Sultan, C. (1976), Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *British Journal of Haematology*; 33(4), 451-8.

Bridger J. M., & Volpi E. (2010), Fluorescence In Situ Hybridization (FISH), Protocols and applications. Vol. 659. New York: Springer.

Chauffaille M.L.L.F, Figueiredo M.S, Beltrani R, Antunes S.V,Yamamoto M, Kerbauy J,(2001), Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques,Brazilian Journal Of Medical and Biological Research,34:735-743.

Chauhan PS,Ihsan R,Singh LC,Gupta D,Mittal V,Kapur S.(2013), Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features,Hindawi Publication Corporation,35(5):581-588.

De Figueiredo AF, De Matos RC, Othman M.A.K, Liehr T, Da Costa ES, Land MGP, Ribeiro RC, Abdelhay E,Silva MLM.(2015), Molecular cytogenetic studies characterizing a novel complex karyotype with an uncommon 5q22 deletion in childhood acute myeloid leukemia, Molecular Cytogenetics, 8:62.

Downward J. (2003), Targeting RAS signalling pathways in cancer therapy. Nat RevCancer, 3(1), pp.11-22.

Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA. (2010), New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. Discov Med **10** (53): 281–92.PMID 21034669.

Frohling S, Gilliland DG, Levine RL., Scholl C, (2005), Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol.23:6285-95.

Frohling S , Schlenk RF, Breitruck J,Benner A, Kreitmeier S,Tobis S, Dohner H, Dohner k,(2002), Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm,Blood,100:4372-4380.

Gaidzik, V., and Döhner, K. (2008), Prognostic implications of gene mutations in acute myeloid leukaemia with normal cytogenetics. Seminars in Oncology, 35(4), 346-355.

Gilliland D. G. (2001), Hematologic malignancies. Current Opinions in Hematology, 8, 189-191.

Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., & Burnett, A. (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. *Blood*, 92(7), 2322-2333.

Grimwade D. (2007), Impact of cytogenetics on clinical outcome in AML. In: *Acute Myelogenous Leukemia*. Karp JE (Ed.). Humana Press, NY, USA, 177–192.

Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., & Burnett, A. K. (2010), Refinement of cytogenetic classification in acute myeloid leukaemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council Trials. Blood, 116(3), 354-365.

Heim S., and Mitelman F. (2009), Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 3rd edition. Cancer Cytogenetics Hoboken, NJ: John Wiley & Sons Inc.

How J,Sykes J, Minden MD, Gupta V, Yee KWL, Schimmer AD, Schuh AC, Kamel-Reid S, Brandwein JM.(2013), The prognostic impact of FLT3-ITD and NPM1 mutations in patients

with relapsed acute myeloid leukemia and intermediate-risk cytogenetics, Blood Cancer Journal, 3.

Huang L, Abruzzo LV, Valbuena JR, Medeiros LJ, Lin P. (2006), Acute Myeloid Leukemia Associated With Variant t(8;21) Detected by Conventional Cytogenetic and Molecular Studies,A Report of Four Cases and Review of the Literature. American Society for Clinical Pathology, 125:267-272.

Joanne Mason, and Michael Griffiths. (2012),Molecular Diagnosis of Leukemia, ExpertRevMol).Diagn.12(5):511526(http://www.medscape.com/viewarticle/ 7667703.

Jones AV, Kreil S, Zoi K *et al.* (2005),Widespread occurrence of the *JAK2* V617F mutation in chronic myeloproliferative disorders. *Blood* 106(6), 2162–2168.

Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Weltermann A**,** Fonatsch C, Haas OA , Mannhalter C, Lechner K, Jaeger U.(2002), Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).The Heamtology Journal,3,28.3-289.

Kelly, L. M., & Gilliland, D. G. (2002),Genetics of myeloid leukemias. Annu Rev GenomicsHum Genet, 3, 179–198.

Lin TL, Williams T, He J, Aljitawi OS, Ganguly S,Abhyankar S, Fleming A, Male H McGuirk JP.(2015), Rates of complete diagnostic testing for patients with acute myeloid leukemia ,Cancer Medicine,4(4):519-522.

Ma X (2010), Hollenbeck A, Cross A , Park Y, Mayne S, Schatzkin A, Sinha R, Wang R, Diet, lifestyle and acute myeloid leukemia in the NIH-ARRP cohort. Am J Epidemiol 171(3): 312-322.

Martens JHA, and Stunnenberg HG. (2010),The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 584:2662-9.

Mehta SV, Shukla SN, Vora HH. (2012), Comprehensive FLT3 Analysis in Indian Acute Myeloid Leukaemia, Journal of Blood Lymph, 2(1).

Moe, W., Kazutaka, K., Yasushi, M., Tomoko, H., Masafumi, T., Shigeki, O., Hisashi, S., & Shuichi, M. (2008), Diagnosis of acute myeloid leukaemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. Int J Hematol, 87, 144–151.

Moorman, A. V., Roman, E., Willett, E. V., Dovey, G. J., Cartwright, R. A., & Morgan, G. J. (2001), Karyotype and age in acute myeloid leukaemia: are they linked? Cancer Genetics and Cytogenetics, 126(2), 155-161.

Morris, C. M. (2011), Chronic myeloid leukaemia: cytogenetic methods and applications for diagnosis and treatment. Methods Mol Biol., 730, 33-61.

Mrozek K, Dohner H, Bloomfield CD. (2007), Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.Curr Opin Hematol. 14:106-14.

Murphy K M., Levis M, Hafez MJ , Geiger T, Cooper LC, B., Smith BD, Small D, Berg KD.(2003), Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay. Journal of Molecular Diagnostics, Vol. 5, No. 2, 96-102.

Raimondi SC. (2000), Fluorescence in situ hybridization: molecular probes for diagnosis of pediatric neoplastic diseases. Cancer Invest. 18(2):135–147.

Santos FPS, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G.(2011), Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia, Cancer,117(10): 2145–2155.

Sacchi N, Magnani I, Kearney L, Wijsman J,Hagemeijer A,Darfler M.(1995),Interphase Cytogenetics of the t(8;21)(q22;q22) Associated with Acute Myelogeneous leukemia by Two-color Fluorescence In Situ Hybridization, Cancer Genetics and Cytogenetics,79:97-103.

Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., Kern, W. (2004), Adult acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 50, 197-222.

Sophia Yohe.(2015), Molecular Genetic Markers in Acute Myeloid Leukemia, Journal of Clinical Medicine,4:460-478.

Starza R, Matteucci C, Crescenzi B, Perla G, Carotenuto M, Martelli MF, Hagemeijer A, Mecucci C.(1997), Identification of Chromosome Changes in Acute Myeloid Leukemia (AML-M2) by Molecular Cytogenetics, Cancer Genetics and Cytogenetics,95:148-152.

Steensma DP. (2006), *JAK2* V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on molecular pathology. *J. Mol. Diagn.* 8(4), 397–411.

Swaminathan S, Garg S, Madkaikar M,Gupta M, Jijina F, Ghosh K.(2014), FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India, Indian Journal of Human Genetics,20(2):160-165.

Trivedi PJ,Patel PS, Brahmbhatt MM, Patel BP, Gajjar SB, Iyer RR,Parikh EH, Shukla SN, Shah PM, Bakshi SR.(2008), A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21), Indian Journal of Human Genetics,14(1):20-22.

Urioste M, Martínez-Ramírez A , Cigudosa JC , Mateo MS, Martínez P, Contra T , Benítez J.(2002), Identification of ins(8;21) with AML1/ETO fusion in acute myelogenous leukemia M2 by molecular cytogenetics ,Cancer Genetics and Cytogenetics,133:83-86.

Velloso ED ,Motta CH, Furtado JB , Bacal NS , Silveira PA, Moyses CB, Sitnik R, Pinho JR.(2011), Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studies,Einstein ,9:184-189.

Williams, B. and Amon, A. (2009), Aneuploidy: Cancer's Fatal Flaw. Cancer Research, 69(13), pp.5289-5291.